Thyroid Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Veröffentlicht von: precision business insights
Veröffentlicht am: 28.03.2018 07:37
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Thyroid Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Pressekontakt:

Thyroid Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Thyroid Carcinoma Disease Pipeline Drugs Assessment

Overview:
Thyroid Carcinomais the most common malignant tumor of endocrine system. Most frequent type of thyroid malignancy is papillary carcinoma. These tumors frequently have genetic alterations leading to activation of mitogen-activated protein kinase (MAPK) signaling pathway. Thyroid carcinoma manifests as a palpable, painless solitary thyroid nodule. Symptoms associated with thyroid carcinoma are solitary nodules, hard and fixed nodules, neck pain, cough, breathing problem, trouble swallowing, voice changes etc.
Thyroid carcinoma diagnosis includes blood test, fine needle aspiration biopsy, CT scan, Ultrasonography, MRI, Indirect laryngoscopy, PET Scan, Nuclear medicine scan etc. Generally, treatment of thyroid cancers includes chemotherapy, hormone therapy, radiation therapy, surgery, targeted therapy.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/thyroid-carcinomadisease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:
By Trial Phase, Thyroid Carcinomapipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Thyroid Carcinomapipeline drugs are segmented as:
• Eisai Inc.
• Pfizer
• Astra Zeneca
• GlaxoSmithKline
• Novartis Pharmaceuticals
• Bayer
• Sanofi
• Celldex Therapeutics
• Genentech, Inc.
• Others
By Drugs, Thyroid Carcinoma pipeline drugs are segmented as:
• Pembrolizumab
• Nivolumab
• Sorafenib
• Sulfatinib
• Anlotinib
• Nab-paclitaxel
• Pazopanib Hydrochloride
• Others
By Types of Thyroid Cancer, Thyroid Carcinoma pipeline drugs are segmented as:
• Papillary Carcinoma
• Follicular Carcinoma
• Hurthle Cell Carcinoma
• Medullary Thyroid Carcinoma
• Anaplastic Carcinoma
By Route of Administration, Thyroid Carcinomapipeline drugs are segmented as:
• Oral
• Parenteral


To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/thyroid-carcinomadisease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu


Space Analysis:
• In March 2017, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.commenced an open Label Phase Ⅱ Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
• In November 2015, Kolltan Pharmaceuticals, Inc., presented pre-clinical findings which determines that Company’s KTN3379 reverses ErbB3-mediated resistance of BARF and MEK inhibitors in BRAF-mutated thyroid cancer and melanoma. Based on these pre-clinical findings support Kolltan’s ongoing Phase 1b clinical trials in BRAF-mutant tumors and the recently initiated clinical trial in thyroid cancer. In November 2016, Celldex Therapeutics, Inc. acquired Kolltan Pharmaceuticals. Kolltens KTN3379 has changed to CDX_3379.

Report Description:
Thyroid CarcinomaDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Thyroid Carcinoma treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Thyroid Carcinoma disease pipeline drugs development. This report studies the dynamics of the Thyroid Carcinoma Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Thyroid Carcinoma disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.


Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/thyroid-carcinomadisease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases


Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/thyroid-carcinomadisease-pipeline-drugs-assessment/
About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com


Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.